PODOXAL 200 Tablets 200 mg

Țară: Tanzania

Limbă: engleză

Sursă: Tanzania Medicinces & Medical Devices Authority

Ingredient activ:

Cefpodoxime Proxetile

Disponibil de la:

Hetero Laboratories Limited, INDIA

Codul ATC:

Cephalosporins

INN (nume internaţional):

Cefpodoxime Proxetile

Dozare:

200 mg

Forma farmaceutică:

Tablets

Produs de:

Hetero Labs Limited, Unit - I, INDIA

Rezumat produs:

Physical description: Orange coloured capsules, shaped film coated tablets debossed with "c" and "3" on one side and plain on the other side; Local technical representative: SURYA PHARMA LIMITED (29253)

Statutul autorizaţiei:

Registered/Compliant

Data de autorizare:

2021-03-29

Caracteristicilor produsului

SUMMARY
OF
PRODUCT
CHARACTERISTICS
1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT
INN NAME: PODOXAL 200 (Cefpodoxime Proxetil Tablets USP 200 mg)
TRADE NAME: PODOXAL 200
STRENGTH: 200 mg
PHARMACEUTICAL FORM: Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film coated tablet contains Cefpodoxime Proxetil USP equivalent
to Cefpodoxime 200 mg.
Excipients: Each 200 mg tablet contains 91.00 mg of Lactose
monohydrate.
3. PHARMACEUTICAL FORM
DOSAGE FORM: Tablets
DESCRIPTION:
Orange coloured oval shaped film coated tablets debossed with ‘C’
and ‘3’ on one side and plain
on the other side
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Cefpodoxime proxetil is indicated for the treatment of patients with
mild to moderate infections
caused by susceptible strains of the designated microorganisms in the
conditions listed below:
Recommended dosages, durations of therapy, and applicable patient
populations vary among
these infections.
ACUTE OTITIS MEDIA caused by Streptococcus pneumoniae (excluding
penicillin resistant strains),
Streptococcus pyogenes, Haemophilus influenzae (including
beta-lactamase-producing strains),
or Moraxella (Branhamella) catarrhalis (including
beta-lactamase-producing strains).
PHARYNGITIS AND/OR TONSILLITIS caused by Streptococcus pyogenes.
NOTE: Only penicillin by the intramuscular route of administration has
been shown to be
effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil
is generally effective in the
eradication of streptococci from the oropharynx. However, data
establishing the efficacy of
cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever
are not available.
COMMUNITY-ACQUIRED PNEUMONIA caused by S. pneumoniae or H. Influenzae
(including beta-
lactamase-producing strains).
ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS caused by S.
pneumoniae, H. influenzae
(non-beta-lactamase-producing strains only), or M. catarrhalis. Data
are insufficient at this time to
establish efficacy in patients with acute bacterial exacerbations of
chroni